Transaction #10639 · Form 4 · 0002015796-25-000003
LENZ Therapeutics, Inc. · Exercise / conversion · Common Stock
LENZ Therapeutics, Inc. · Transacted November 17, 2025 · Filed November 19, 2025
What does this filing report?
An SEC Form 4 filing for LENZ Therapeutics, Inc. records an exercise / conversion involving Common Stock on November 17, 2025. The reported quantity was 10,000. The filing date is November 19, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- LENZ Therapeutics, Inc.
- Company CIK
- 0001815776
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 10,000
- Reported price
- 2.08
- Reference value
- 20,800
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 14,733
- Ownership description
- Not reported
- SEC acceptance time
- Nov 19, 2025, 7:02 PM EST
- 10b5-1 indication
- Indicated in filing
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Olsson Shawn ↗
Chief Commercial Officer
CIK 0002015796
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on August 12, 2025.
- F2
- Represents the weighted average share price of an aggregate total of 4,212 shares sold in the price range of $25.12 to $26.11 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3
- Represents the weighted average share price of an aggregate total of 5,788 shares sold in the price range of $26.12 to $26.81 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4
- Shares issued pursuant to the LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.) 2020 Equity Incentive Plan (the "2020 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2020 Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean April 26, 2021.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.